Clinical trials: Parkinsonian Disorders
- Condition Parkinsonian Disorders
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Volunteers
Phase 1 Study of NPT200-11 in Healthy Subjects
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered NPT200-11 in healthy subjects. In addition, the maximally tolerated dose will be determined.
- Trial name
- NCT02606682
- Testing
- NPT200-11
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Neuropore Therapies Inc.
Parkinson Disease
Quality-of-Life Index (Q-Index)
The main objective of this observational study is to use commonly-used connected objects (smartphones and smartwatches) to remotely assess and monitor the health-related quality of life (HrQoL) of people with Parkinson's disease…
- Trial name
- NCT06209502
- Where
- 4 sites in Belgium
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Koios Care
Parkinson's Disease (PD)
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.
- Trial name
- NCT02169427
- Testing
- OPC
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease, Genetic Predisposition
Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
A case-control study to identify microbiome and genetic differences between healthy subjects and patients with incident Parkinson's disease.
- Trial name
- NCT04119596
- Testing
- 16S rRNA gene sequencing, DNA-microarray genotyping
- Where
- Russia
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Atlas Biomed
Parkinson's Disease
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
The purpose of the study is to evaluate the safety and tolerability after administration of multiple doses and the pharmacokinetics (PK) of single and multiple doses of UCB0599 in healthy study participants and participants with…
- Trial name
- NCT04875962
- Testing
- UCB0599
- Where
- 6 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Parkinson Disease
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects
The Safety, Tolerability, Pharmacokinetic and Food Effect Study of HEC122505MsOH Tablets in Healthy Subjects
- Trial name
- NCT04625361
- Testing
- HEC122505MsOH
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.
- Trial name
- NCT01536366
- Testing
- BIA 9-1067, Repaglinide
- Where
- Portugal
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
- Trial name
- NCT05523570
- Testing
- HNC364
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Parkinson's Disease, Essential Tremor
Movement Disorder Quantification Algorithm Development
The purpose of this study is to collect kinematic motion data from subjects with movement disorders such as Parkinson's disease (PD) and essential tremor (ET) to develop and validate algorithms for quantifying motor symptoms such…
- Trial name
- NCT01534650
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease
Pharmacokinetic Study in Healthy Volunteers
Phase I open, randomized cross-over pharmacokinetic study.
- Trial name
- NOCOFPK2 (NCT02554734)
- Testing
- levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone
- Where
- Finland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson Disease
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
- Trial name
- NCT06466525
- Testing
- LBT-3627
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Longevity Biotech Australia Pty Ltd (subsidiary)
Parkinson's Disease
Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.
- Trial name
- NCT04165837
- Testing
- FB-101
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Parkinson's Disease
Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202
The purpose of this study is to investigate the tolerability and safety of three multiple dose regimens of nebicapone (BIA 3-202 100 mg, 200 mg, and 300 mg 6 times daily) in healthy volunteers.
- Trial name
- NCT02772627
- Testing
- Nebicapone
- Where
- Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease, Healthy
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
The primary objective of the study is to evaluate the safety and tolerability of a range of single BIIB054 doses, administered as a single intravenous (IV) infusion, in healthy participants and participants with early Parkinson's…
- Trial name
- NCT02459886
- Testing
- BIIB054
- Where
- 9 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Biogen
Parkinson's Disease (PD)
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT02169440
- Testing
- BIA 9-1067, Warfarin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.
- Trial name
- NCT01519284
- Testing
- BIA 9-1067 5 mg, Entacapone, levodopa/carbidopa
- Where
- Portugal
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's…
- Trial name
- NCT00593606
- Testing
- Rotigotine
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Parkinson's Disease
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
The purpose of this study is to evaluate the influence of repeated oral doses of KW-6356 on the pharmacokinetics of index substrates for CYP3A4/5, CYP1A2 and BCRP.
- Trial name
- NCT03970798
- Testing
- Midazolam, Caffeine, Rosuvastatin
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.
- Trial name
- NCT05581823
- Testing
- Tavapadon, Carbamazepine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC